Active U.S. drug shortages increased to 227 in the second quarter of 2026, marking the third consecutive quarterly increase, according to the American Society of Health-System Pharmacists. Nearly half of all new shortages this year involve medications made by a single manufacturer, a concentration that increases supply chain vulnerability, and the FDA’s database continues to reflect new discontinuations weekly.
Here are five recent drug shortages, according to the FDA database:
- Arsenic trioxide injection: Fresenius Kabi discontinued its 1-milligram/1-milliliter presentation of the leukemia treatment Sept. 21, citing discontinuation of manufacture. A second manufacturer, Ingenus Pharmaceuticals, discontinued its own version of the drug in February.
- Rivaroxaban for suspension: Janssen Pharmaceuticals discontinued its 155-milligram Xarelto oral suspension Sept. 18, citing a business decision.
- Rivastigmine extended-release film: Mylan discontinued its 4.6-milligram/24-hour presentation of the Alzheimer’s and Parkinson’s dementia patch Sept. 18, citing discontinuation of manufacture.
- Melphalan hydrochloride injection: Fresenius Kabi discontinued its injection kit presentation of the chemotherapy drug Sept. 16, citing discontinuation of manufacture.
- Mesalamine extended-release capsules: Mylan discontinued its 0.375-gram presentation of the ulcerative colitis treatment in late August, citing discontinuation of manufacture.
